75Pharma Group Limited

	Page
Balance Sheet	1
Notes to the Financial Statements	2—4

1. General Information

75Pharma Group Limited is a private company, limited by shares, incorporated in England & Wales, registered number 13152498 . The registered office is 123 Buckingham Palace Road, London, SW1W 9SH.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

Summary of disclosure exemptions

The company has taken advantage of the exemption in section 398 of the Companies Act 2006 from the requirement to prepare consolidated financial statements on the grounds that it is a small sized group.

2.2. Going Concern Disclosure

The directors have considered the company's financial position, liquidity and future performance together with financial projections. After making enquiries, the directors are satisfied that the company has sufficient resources to continue in operation for the forseeable future, being at least 12 months from the date of signing the financial statements. Accordingly, they continue to adopt the going concern basis in preparing the company's financial statements.

2.3. Significant judgements and estimations

There are no critical judgements or key sources of estimation made by the directors in the process of applying the company's accounting policies which have a significant effect on the amounts recognised in the financial statements.

2.4. Financial Instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2.5. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

2.6. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

2.7. Pensions

The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.

Page 2

Page 3

75Pharma Group Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2024

2.8. Debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

2.9. Creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2.10. Investments

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 1 (2023: 1)

4. Investments

	Subsidiaries
	£
Cost or Valuation
As at 1 January 2024	24,888
Additions	94,900

As at 31 December 2024	119,788

Provision
As at 1 January 2024	-

As at 31 December 2024	-

Net Book Value
As at 31 December 2024	119,788

As at 1 January 2024	24,888

Details of the investments in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking	Registered Office	Holding	% 2024	% 2023
75Pharma Limited	123 Buckingham Palace Road, London, SW1W 9SH, UK.	Ordinary	100%	100%
75Pharma AB	Malmskillnadsgatan 44 A, 111 57, Stockholm, Sweden.	Ordinary	100%	100%
75Pharma OY	Mikonkatu 9, 00100, Helsinki, Finland.	Ordinary	100%	100%

5. Debtors

	2024	2023
	£	£
Due within one year
Other debtors	41,554	8,721
Amounts owed by group undertakings	383,538	220,613

	425,092	229,334

The amounts owed by group companies are unsecured, carry no interest and are repayable on demand.

Page 3

Page 4

75Pharma Group Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2024

6. Creditors: Amounts Falling Due Within One Year

	2024	2023
	£	£
Trade creditors	7,262	13,103
Other taxes and social security	-	7,477
Other creditors	2,093,604	290,488
Accruals and deferred income	155,630	74,750
Amounts owed to group undertakings	62,827	-

	2,319,323	385,818

The amounts owed to group companies are unsecured, carry no interest and are repayable on demand.

7. Share Capital

	2024	2023
	£	£
Allotted, Called up and fully paid	2,173	1,173

Reserves

The retained earnings reserve represents cumulative profit or losses net of dividends paid and other adjustments.

Share premium reserve represents premium paid for new shares above their nominal value net of issue costs This reserve forms part of the company's non-distributable reserves.

The amount previously presented as capital contribution reserve has been restructured and is currently classified within other creditors as an amount due to one of the shareholders (and director) of the company.

During the period 10,000,000 shares were issued for an amount of £243,000.

8. Directors Advances, Credits and Guarantees

Included within other creditors are the following loans to directors:

	As at 1 January 2024	Amounts advanced	Amounts repaid	Amounts written off	As at 31 December 2024
	£	£	£	£	£
Mr Pasi Ruokostenohja	-	(1,811,055 )	-	-	(1,811,055 )
Mr Niko Nevala	-	(208,160 )	-	-	(208,160 )

The above loans are unsecured, interest free and repayable on demand.

9. Related Party Transactions

The company wholly owns the subsidiary members of the group and has therefore taken advantage of the provisions of Section 33.1A of FRS102 not to disclose transactions with entities that are wholly owned members of the group. There were no other related part transactions to disclose.

10. Ultimate Controlling Party

There is no controlling party.

Page 4

		2024		2023
	Notes	£	£	£	£
FIXED ASSETS
Investments	4		119,788		24,888

			119,788		24,888
CURRENT ASSETS
Debtors	5	425,092		229,334
Cash at bank and in hand		1,278		1,828

		426,370		231,162
Creditors: Amounts Falling Due Within One Year	6	(2,319,323 )		(385,818 )

NET CURRENT ASSETS (LIABILITIES)			(1,892,953 )		(154,656 )

TOTAL ASSETS LESS CURRENT LIABILITIES			(1,773,165 )		(129,768 )

NET LIABILITIES			(1,773,165 )		(129,768 )

CAPITAL AND RESERVES
Called up share capital	7		2,173		1,173
Share premium account			1,536,827		1,294,827
Other reserves			-		341,880
Profit and Loss Account			(3,312,165 )		(1,767,648 )

SHAREHOLDERS' FUNDS			(1,773,165)		(129,768)